Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab and Nisevokitug Combinations in Myelofibrosis
NCT04283526Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of sabatolimab and nisevokitug in myelofibrosis (MF) (5 arms), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities at 12 months, Incidence and severity of Adverse Events and Serious Adverse Events at 36 months and 3 more. Planned start Nov 2020; status: withdrawn.
02
Drugs
sabatolimabnisevokitug
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04283526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04283526.